Original Query: ALL
Previous Study | Return to List | Next Study

Evaluation of Two Doses of QVAR by Breath Operated and Metered Dose Inhalers in Asthmatic Children

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00094016
Recruitment Status : Completed
First Posted : October 11, 2004
Last Update Posted : May 12, 2014
Information provided by (Responsible Party):
Teva Pharmaceutical Industries ( Teva Branded Pharmaceutical Products, R&D Inc. )

Brief Summary:
The primary objective of this study is to compare the QVAR-Easi-Breathe 100 mcg/day and QVAR-Easi-Breathe 200 mcg/day with placebo relative to changes in forced expiratory volume in 1 second (FEV1) results following 12 weeks of treatment. Secondary objectives such as daily asthma symptoms scores (per week), morning peak expiratory flow (PEF) values, nocturnal awakening and utilization of rescue medication per day also will be evaluated. In addition, an exploratory evaluation will assess the comparability of the two devices (i.e., QVAR-Easi-Breathe versus QVAR-MDI) at the same dose levels.

Condition or disease Intervention/treatment Phase
Asthma Drug: beclomethasone dipropionate Phase 3

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 440 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Safety and Efficacy Evaluation of Two Doses of HFA-Propelled Beclomethasone Dipropionate (QVAR) Versus Placebo by Breath Operated and Metered Dose Inhalers in Mild to Moderate Asthmatic Children
Study Start Date : October 2004
Primary Completion Date : June 2006
Study Completion Date : June 2006

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Asthma
U.S. FDA Resources

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   5 Years to 11 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female children aged 5 through 11 years at the screening visit
  • Documented clinical evidence of asthma (FEV1 = 65-90%)
  • Ability to perform acceptable and reproducible spirometry per ATS guidelines
  • Ability to perform PEF determinations
  • Reversible bronchoconstriction as verified by >12% increase in FEV1
  • Otherwise healthy children with clinically-acceptable medical history, physical examination, vital signs and clinical laboratory parameters within the acceptable ranges for asthma patients
  • The parent or guardian must be willing to give written informed consent as well as the patient assent and be able to adhere to the dose and visit schedule.

Exclusion Criteria:

  • Patients who have used inhaled corticosteroids within 30 days prior to the screening visit.
  • Allergy or sensitivity to beclomethasone dipropionate (BDP) or to other components of the formulations used in the CTM
  • Patients demonstrating an increase or decrease in FEV1 >20% between the screening and baseline visit.
  • Patients who are unable to use a metered dose inhaler (MDI) without a spacer device.
  • Patients requiring the use of >12 puffs per day of albuterol for any 3 consecutive days between the screening and baseline visits.
  • Patients with evidence of growth retardation
  • Patients who have been treated with methotrexate, cyclosporin, gold or other cytotoxic agents for the control of asthma or for a concurrent condition within the last 3 months.
  • Patients who are receiving escalating doses of immunotherapy, oral immunotherapy or short course (rush) immunotherapy for rhinitis.
  • Patients with evidence (on physical exam) of oropharyngeal candidiasis.
  • Exposure to investigational drugs within 30 days prior to the screening visit
  • Require continuous treatment with beta blockers MAO inhibitors, tricyclic antidepressants, anticholinergics, inhaled nedocromil or cromolyn, or nebulized therapy (excluding sponsor provided albuterol MDI)
  • Inability to tolerate or unwillingness to comply with required washout periods for all applicable medications
  • Treatment at any time for life-threatening asthmatic episodes (e.g., episodes requiring intubation and/or associated with the development of hypercapnia, hypoxia and seizures, etc.)
  • Patients that have received any of the following treatments or met any of the following conditions within six weeks prior to the screening visit:

    • Oral or injectable corticosteroids
    • an upper respiratory tract infection and/or sinusitis associated with exacerbation of asthmatic symptoms
    • emergency room treatment or hospitalization for asthmatic symptoms.
  • History and/or presence of any non-asthmatic acute or chronic lung disease, including but not limited to bronchitis (within the previous 6 months), emphysema, active tuberculosis, bronchiectasis or cystic fibrosis.
  • Presence of any clinically-significant cardiovascular disease (including cardiac arrhythmias and uncontrolled hypertension), clinically-significant hepatic, renal, or endocrine dysfunction, stroke, uncontrolled diabetes, hyperthyroidism, convulsive disorders, neoplastic disease other than basal cell carcinoma, and significant psychiatric disease.
  • History of glaucoma or cataracts
  • Presence of systemic fungal, bacterial, viral or parasitic infections and/or ocular herpes simplex
  • Unlikely to be compliant, take study medication as directed, complete the diary cards, or attend scheduled clinic visits as required.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00094016

  Hide Study Locations
United States, California
Allergy and Asthma Specialists
Huntington Beach, California, United States, 92647
Pediatric Care Medical Group
Huntington Beach, California, United States, 92647
West Coast Clinical Trials
Long Beach, California, United States, 90806
Southern California Research
Mission Viejo, California, United States, 92691
Clinical Trials of Orange County, Inc.
Orange, California, United States, 92868
California Allergy & Asthma
Palmdale, California, United States, 93551
Center for Clinical Trials, LLC
Paramount, California, United States, 90723
Integrated Research Group
Riverside, California, United States, 92506
Allergy Associates Medical Group
San Diego, California, United States, 92120
Allergy and Asthma Medical Group
Walnut Creek, California, United States, 94598
United States, Florida
Allergy & Asthma Care of Florida
Ocala, Florida, United States, 34471
United States, Georgia
New Horizon's Health Research
Atlanta, Georgia, United States, 30309
AeroAllergy Research Labs of Savanna, Inc
Savannah, Georgia, United States, 31406
United States, Illinois
Sneeze, Wheeze and Itch Associates
Normal, Illinois, United States, 61761
United States, Kentucky
Family Allergy & Asthma Research Institute
Lousiville, Kentucky, United States, 40215
United States, Louisiana
Perez-Betancourt Medical Clinic
Metairie, Louisiana, United States, 70001
United States, Massachusetts
NorthEast Medical Research Associates
North Dartmouth, Massachusetts, United States, 02747
United States, Minnesota
Clinical Research Institute
Plymouth, Minnesota, United States, 55441
United States, Nebraska
The Asthma and Allergy Center
Papillion, Nebraska, United States, 68046-4194
United States, New York
Asthma and Allergy Associates, PC
Ithaca, New York, United States, 14850
St.Elizabeth's Children's Health Center
Utica, New York, United States, 13502
United States, North Carolina
Regional Allergy and Asthma Consultants
Asheville, North Carolina, United States, 28805
United States, Ohio
Allergy & Respiratory Center
Canton, Ohio, United States, 44718
Dayton Clinical Research Center
Dayton, Ohio, United States, 45406
United States, Oklahoma
Dr. Santiago Reyes
Oklahoma City, Oklahoma, United States, 73112
Allergy and Asthma Clinical Research Center
Oklahoma City, Oklahoma, United States, 73120
United States, Oregon
Allergy and Asthma Research Groups
Eugene, Oregon, United States, 97401
Allergy, Asthma & Dermatology Research Center
Lake Oswego, Oregon, United States, 97035
Clinical Research Institute of Southern Oregon, PC
Medford, Oregon, United States, 97504
Allergy Associates Research Center
Portland, Oregon, United States, 97213
United States, Pennsylvania
Allergy & Clinical Immunology Associates
Pittsburg, Pennsylvania, United States, 15241
United States, Tennessee
The Allergy Asthma and Sinus Center
Knoxville, Tennessee, United States, 37922
United States, Texas
Pediatric Allergy/Immunology Assoc.
Dallas, Texas, United States, 75230
Pharmaceutical Research and Consulting, Inc.
Dallas, Texas, United States, 75231
Allergy and Asthma Associates
Houston, Texas, United States, 77054
United States, Virginia
Virginia Adult & Pediatric Allergy & Asthma
Richmond, Virginia, United States, 23229
United States, Washington
Spokane Allergy and Asthma Clinical Research
Spokane, Washington, United States, 99204
Puerto Rico
Centro Neumologia Pediatrica
Hato Rey, Puerto Rico, 00917
Ponce School of Medicine
Ponce, Puerto Rico, 00732
Sponsors and Collaborators
Teva Branded Pharmaceutical Products, R&D Inc.

Responsible Party: Teva Branded Pharmaceutical Products, R&D Inc. Identifier: NCT00094016     History of Changes
Other Study ID Numbers: IXR-302-25-197
First Posted: October 11, 2004    Key Record Dates
Last Update Posted: May 12, 2014
Last Verified: May 2014

Additional relevant MeSH terms:
Anti-Inflammatory Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents